Table 1. Baseline demographics (N= 116)*.
| Age, y | 72.4 ±4.6 |
| Education, y | 16.3 ±2.5 |
| Women, N | 61 (52.6%) |
| Race, Caucasian, N | 105 (90.5%) |
| APOE4+, N | 33 (28.4%) |
| Biomarkers | |
| CSF Aβ42, pg/mL | 864.2 ± 325.7 |
| CSF tau, pg/mL | 347.5 ± 197.6 |
| CSF ptau181, pg/mL | 63.3 ± 30.0 |
| CSF tau/Aβ42 | 0.50 ± 0.49 |
| CSF ptau181/Aβ42 | 0.90 ± 0.08 |
| Participant endorsing some mood/NPS problems | |
| POMS TMD, N | 25 (21.5%) |
| Normal CSF biomarker | 10 (8.4%) |
| Abnormal CSF biomarker | 15 (12.9%) |
| GDS, N | 59 (50.8%) |
| Normal CSF biomarker | 25 (21.5%) |
| Abnormal CSF biomarker | 34 (29.3%) |
| NPI-Q, N | 31 (26.7%) |
| Normal CSF biomarker | 18 (15.5%) |
| Abnormal CSF biomarker | 13 (11.2%) |
APOE4+, Apolipoprotein allele ε4; Aβ42, amyloid-β42; ptau181, phosphorylated tau181; POMS-SF, Profile of Mood States – Short Form; TMD, Total Mood Disturbance; GDS, Geriatric Depression Scale; NPI-Q, Neuropsychiatric Inventory Questionnaire.
*
Mean±SD or percentage.